Jasmien Wellens

854 total citations
29 papers, 479 citations indexed

About

Jasmien Wellens is a scholar working on Pulmonary and Respiratory Medicine, Gastroenterology and Oncology. According to data from OpenAlex, Jasmien Wellens has authored 29 papers receiving a total of 479 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Pulmonary and Respiratory Medicine, 15 papers in Gastroenterology and 11 papers in Oncology. Recurrent topics in Jasmien Wellens's work include Sarcoma Diagnosis and Treatment (23 papers), Gastrointestinal Tumor Research and Treatment (15 papers) and Gastric Cancer Management and Outcomes (10 papers). Jasmien Wellens is often cited by papers focused on Sarcoma Diagnosis and Treatment (23 papers), Gastrointestinal Tumor Research and Treatment (15 papers) and Gastric Cancer Management and Outcomes (10 papers). Jasmien Wellens collaborates with scholars based in Belgium, United States and Switzerland. Jasmien Wellens's co-authors include Patrick Schöffski, Agnieszka Woźniak, Raf Sciot, Maria Dêbiec‐Rychter, Thomas Van Looy, Jasmien Cornillie, Ulla Vanleeuw, Yemarshet K. Gebreyohannes, Haifu Li and Giuseppe Floris and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Scientific Reports.

In The Last Decade

Jasmien Wellens

28 papers receiving 474 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jasmien Wellens Belgium	14	304	219	149	114	108	29	479
Ulla Vanleeuw Belgium	11	234 0.8×	165 0.8×	139 0.9×	92 0.8×	78 0.7×	22	400
Yemarshet K. Gebreyohannes Belgium	11	185 0.6×	131 0.6×	105 0.7×	86 0.8×	66 0.6×	22	322
Ann W. Gramza United States	10	181 0.6×	138 0.6×	200 1.3×	137 1.2×	47 0.4×	22	552
Shih-Chen Yu Taiwan	14	256 0.8×	63 0.3×	142 1.0×	217 1.9×	35 0.3×	17	589
Hyuk‐Chan Kwon South Korea	9	139 0.5×	100 0.5×	146 1.0×	121 1.1×	20 0.2×	19	348
Feng-yi Feng China	8	345 1.1×	90 0.4×	450 3.0×	177 1.6×	19 0.2×	35	673
Amadeu Pimenta Portugal	13	276 0.9×	138 0.6×	126 0.8×	145 1.3×	23 0.2×	19	454
Izuma Nakayama Japan	14	450 1.5×	103 0.5×	527 3.5×	123 1.1×	8 0.1×	108	820
Hideki Ushiku Japan	15	191 0.6×	55 0.3×	159 1.1×	228 2.0×	8 0.1×	39	478
Richard Ong Singapore	9	110 0.4×	60 0.3×	116 0.8×	207 1.8×	28 0.3×	20	413

Countries citing papers authored by Jasmien Wellens

Since Specialization

Citations

This map shows the geographic impact of Jasmien Wellens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jasmien Wellens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jasmien Wellens more than expected).

Fields of papers citing papers by Jasmien Wellens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jasmien Wellens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jasmien Wellens. The network helps show where Jasmien Wellens may publish in the future.

Co-authorship network of co-authors of Jasmien Wellens

This figure shows the co-authorship network connecting the top 25 collaborators of Jasmien Wellens. A scholar is included among the top collaborators of Jasmien Wellens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jasmien Wellens. Jasmien Wellens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wellens, Jasmien, et al.. (2025). Cysteine-selective [¹⁸⁸Re]Re(v) radiolabelling of a Nanobody® for targeted radionuclide therapy using a “chelate-then-click” approach. Chemical Science. 16(14). 6089–6098. 1 indexed citations

Crabbé, Melissa, Virginie Neirinckx, Jasmien Wellens, et al.. (2024). Preclinical evaluation of CXCR4 peptides for targeted radionuclide therapy in glioblastoma. EJNMMI Radiopharmacy and Chemistry. 9(1). 52–52. 2 indexed citations

Woźniak, Agnieszka, Andrea Casazza, Jasmien Wellens, et al.. (2022). Enhanced Antitumor Efficacy of PhAc-ALGP-Dox, an Enzyme-Activated Doxorubicin Prodrug, in a Panel of THOP1-Expressing Patient-Derived Xenografts of Soft Tissue Sarcoma. Biomedicines. 10(4). 862–862. 1 indexed citations

Woźniak, Agnieszka, Thomas Van Cann, Jasmien Wellens, et al.. (2021). Establishment of an Academic Tissue Microarray Platform as a Tool for Soft Tissue Sarcoma Research. Sarcoma. 2021. 1–12. 6 indexed citations

Gebreyohannes, Yemarshet K., Yanis Tolstov, Jasmien Wellens, et al.. (2020). Differential antitumor activity of compounds targeting the ubiquitin-proteasome machinery in gastrointestinal stromal tumor (GIST) cells. Scientific Reports. 10(1). 5178–5178. 9 indexed citations

Woźniak, Agnieszka, Jasmien Wellens, Yemarshet K. Gebreyohannes, et al.. (2020). Plocabulin, a novel tubulin inhibitor, has potent antitumor activity in patient-derived xenograft models of gastrointestinal stromal tumors. Translational Oncology. 13(11). 100832–100832. 14 indexed citations

Cornillie, Jasmien, Agnieszka Woźniak, Haifu Li, et al.. (2019). Establishment and Characterization of Histologically and Molecularly Stable Soft-tissue Sarcoma Xenograft Models for Biological Studies and Preclinical Drug Testing. Molecular Cancer Therapeutics. 18(6). 1168–1178. 27 indexed citations

Cornillie, Jasmien, Agnieszka Woźniak, Yemarshet K. Gebreyohannes, et al.. (2019). Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification. Clinical & Translational Oncology. 22(4). 546–554. 46 indexed citations

Cornillie, Jasmien, Agnieszka Woźniak, Jasmien Wellens, et al.. (2019). Assessment of the platelet-derived growth factor receptor alpha antibody olaratumab in a panel of patient-derived soft tissue sarcoma xenografts. BMC Cancer. 19(1). 724–724. 5 indexed citations

10.

Gebreyohannes, Yemarshet K., Elizabeth A. Burton, Agnieszka Woźniak, et al.. (2018). PLX9486 shows anti-tumor efficacy in patient-derived, tyrosine kinase inhibitor-resistant KIT-mutant xenograft models of gastrointestinal stromal tumors. Clinical and Experimental Medicine. 19(2). 201–210. 15 indexed citations

11.

Gebreyohannes, Yemarshet K., Agnieszka Woźniak, Jasmien Wellens, et al.. (2018). Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors. Clinical Cancer Research. 25(2). 609–618. 57 indexed citations

12.

Woźniak, Agnieszka, Jasmien Wellens, Yemarshet K. Gebreyohannes, et al.. (2018). Abstract 3840: Plocabulin, a tubulin inhibitor, presents antitumor activity in patient-derived xenograft (PDX) models of gastrointestinal stromal tumor (GIST). Cancer Research. 78(13_Supplement). 3840–3840. 1 indexed citations

13.

Cornillie, Jasmien, Agnieszka Woźniak, Péter Pokreisz, et al.. (2017). In Vivo Antitumoral Efficacy of PhAc-ALGP-Doxorubicin, an Enzyme-Activated Doxorubicin Prodrug, in Patient-Derived Soft Tissue Sarcoma Xenograft Models. Molecular Cancer Therapeutics. 16(8). 1566–1575. 16 indexed citations

14.

Gebreyohannes, Yemarshet K., Patrick Schöffski, Thomas Van Looy, et al.. (2016). Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations. Molecular Cancer Therapeutics. 15(12). 2845–2852. 29 indexed citations

15.

Looy, Thomas Van, Agnieszka Woźniak, Giuseppe Floris, et al.. (2015). Therapeutic Efficacy Assessment of CK6, a Monoclonal KIT Antibody, in a Panel of Gastrointestinal Stromal Tumor Xenograft Models. Translational Oncology. 8(2). 112–118. 13 indexed citations

16.

Looy, Thomas Van, Agnieszka Woźniak, Giuseppe Floris, et al.. (2014). Phosphoinositide 3-Kinase Inhibitors Combined with Imatinib in Patient-Derived Xenograft Models of Gastrointestinal Stromal Tumors: Rationale and Efficacy. Clinical Cancer Research. 20(23). 6071–6082. 42 indexed citations

17.

Li, Haifu, Agnieszka Woźniak, Raf Sciot, et al.. (2014). Pazopanib, a Receptor Tyrosine Kinase Inhibitor, Suppresses Tumor Growth through Angiogenesis in Dedifferentiated Liposarcoma Xenograft Models. Translational Oncology. 7(6). 665–671. 36 indexed citations

18.

Looy, Thomas Van, Yemarshet K. Gebreyohannes, Agnieszka Woźniak, et al.. (2014). Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors. PubMed. 4(1). 10–10. 22 indexed citations

19.

Floris, Giuseppe, Agnieszka Woźniak, Raf Sciot, et al.. (2012). A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment Withdrawal. Clinical Cancer Research. 19(3). 620–630. 59 indexed citations

20.

Floris, Giuseppe, Raf Sciot, Agnieszka Woźniak, et al.. (2011). The Novel HSP90 Inhibitor, IPI-493, Is Highly Effective in Human Gastrostrointestinal Stromal Tumor Xenografts Carrying Heterogeneous KIT Mutations. Clinical Cancer Research. 17(17). 5604–5614. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact